Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2020
October 29 2020 - 4:05PM
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the
Company will release results for its third quarter of 2020 ended
September 30, 2020, before the market opens on Friday, November
6th, 2020, and will hold a conference call to discuss its financial
results at 9:00 a.m. Pacific Time.
To access the conference call, dial toll free
(877) 881-2595, five minutes before the conference. The passcode
for the conference call is 7086853.
The call can also be accessed on the Investors
page on the Company’s website www.amphastar.com.
Amphastar is a specialty pharmaceutical company
that primarily develops, manufactures, markets, and sells generic
and proprietary injectable and inhalation products, including
products with high technical barriers to market entry. Most of the
Company’s products are used in hospital or urgent care clinical
settings and are primarily contracted and distributed through group
purchasing organizations and drug wholesalers.
Forward Looking Statements
All statements in this press release and in the
conference call referenced above that are not historical are
forward-looking statements, including, among other things,
statements relating to the Company’s expectations regarding future
financial performance, backlog, sales and marketing of its
products, market size and growth, the timing of FDA filings or
approvals, including the DMFs of ANP, the timing of product
launches, acquisitions and other matters related to its pipeline of
product candidates, its share buyback program and other future
events, such as the impact of the COVID-19 pandemic and related
responses of business and governments to the pandemic on our
operations and personnel, and on commercial activity and demand
across our business operations and results of operations. These
statements are not historical facts but rather are based on
Amphastar’s historical performance and its current expectations,
estimates, and projections regarding Amphastar’s business,
operations, and other similar or related factors. Words such as
“may,” “might,” “will,” “could,” “would,” “should,” “anticipate,”
“predict,” “potential,” “continue,” “expect,” “intend,” “plan,”
“project,” “believe,” “estimate,” and other similar or related
expressions are used to identify these forward-looking statements,
although not all forward-looking statements contain these words.
You should not place undue reliance on forward-looking statements
because they involve known and unknown risks, uncertainties, and
assumptions that are difficult or impossible to predict and, in
some cases, beyond Amphastar’s control. Actual results may
differ materially from those in the forward-looking statements as a
result of a number of factors, including those described in
Amphastar’s filings with the Securities and Exchange Commission,
including in the Annual Report on Form 10-K for the year ended
December 31, 2019, filed with the SEC on March 16, 2020. In
particular, the extent of COVID-19’s impact on our business will
depend on several factors, including the severity, duration and
extent of the pandemic, as well as actions taken by governments,
businesses, and consumers in response to the pandemic, all of which
continue to evolve and remain uncertain at this time. You can
locate these reports through the Company’s website at
http://ir.amphastar.com and on the SEC’s website at
www.sec.gov. The forward-looking statements in this release
speak only as of the date of the release. Amphastar undertakes no
obligation to revise or update information or any forward-looking
statements in this press release or the conference call referenced
above to reflect events or circumstances in the future, even if new
information becomes available or if subsequent events cause
Amphastar’s expectations to change.
Contact:
William J. Peters Chief Financial Officer (909)
980-9484
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Apr 2023 to Apr 2024